Background: This study was initiated to determine practices patterns in adjuvant chemotherapy for non-metastatic breast cancer and to examine the relationship between received dose intensity (RDI) and survival in patients with breast cancer Nigeria. Methods: Our study was a retrospective analysis of patients with breast cancer recruited from 2012 and 2015. A total of 204 patients were initially entered into the study, 102 were lost to follow-up leaving 102 patients who were suitable for the survival analysis. Survival time was calculated from 106 days, the scheduled end of chemotherapy. Results: The total average RDI for patients was 74%. Over the 204 patients that were reviewed, 144 (70.6%) had some reduction of RDI. This subgroup had an average RDI of 63%. On average, 79% of the intended dose of chemotherapy was given. The time to completion of chemotherapy was 1.33 times that specified by the protocol. Dose delays an overall reduction was mainly attributed to intolerability and financial constraints. Survival by RDI showed a significant decrease in survival rate for patients with RDI of >49% (Hazard Ratio = 3.473, 95% CI 1.21 - 9.91, P = 0.020); RDI of 50% - 59% (Hazard Ratio = 3.916, 95% CI 1.01 - 15.18, P = 0.048); RDI of 60% - 69% (Hazard Ratio = 4.462, 95% CI 1.65 - 12.03, P = 0.003) compared with patients who received an RDI of 100%. Although associated with poorer prognosis, there were no significant changes in the survival rate for patients with RDI of 70% - 79% (Hazard Ratio = 1.667, 95% CI 0.56 - 4.96, P = 0.359); RDI of 80% - 89% (Hazard Ratio = 1.620, 95% CI 0.47 - 5.53, P = 0.441); RDI 90% - 99% (Hazard Ratio = 1.590, 95% CI 0.53 - 4.73, P = 0.405) compared with patients who received an RDI of 100%. Conclusion: This study provides evidence that decreased RDI of <70% in non-metastatic breast cancer patients is strongly associated with decreased overall survival.
References
[1]
Akinde, O.R., Phillips, A.A., Oguntunde, O.A., et al. (2015) Cancer Mortality Pattern in Lagos University Teaching Hospital, Lagos, Nigeria. Journal of Cancer Epidemiology, 2015, Article ID: 842032. https://doi.org/10.1155/2015/842032
[2]
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[3]
Azubuike, S.O., Hayes, L., Sharp, L., Alabi, A., Oyesegun, R. and McNally, R. (2022) Socio-Economical Status and the Risk of Breast Cancer among Nigerian Women: A Case Control Study. The Pan African Medical Journal, 41, Article 175. https://doi.org/10.11604/pamj.2022.41.175.32914
[4]
Ogundiran, T.O., Huo, D., Adenipekun, A., Campbell, O., Oyesegun, R., Akang, E., Adebamowo, C. and Olapode, O.I. (2012) Body Fat Distribution and Breast Cancer Risk: Findings from the Nigerian Breast Cancer Study. Cancer Causes & Control, 23, 565-574. https://doi.org/10.1007/s10552-012-9916-y
[5]
Wild, C.P., Weiderpass, E., Steward, B.W. (2020) World Cancer Report: Cancer Research for Cancer Prevention. International Agency for Research on Cancer.
[6]
Lauby-Secretan, B., Scoccianti, C., Loomis, D., et al. (2015) Breast Cancer Screening—Viewpoint of the IARC Working Group. The New England Journal of Medicine, 372, 2353-2358. https://doi.org/10.1056/NEJMsr1504363
[7]
Unger-Saldana, K. (2014) Challenges to the Early Diagnosis and Treatment of Breast Cancer on Developing Countries. World Journal of Clinical Oncology, 5, 465-477. https://doi.org/10.5306/wjco.v5.i3.465
[8]
Azizun-Nisa, Bhurgri, Y., Raza, F. and Kayani, N. (2008) Comparison of ER, PR & HER 2/Neu (C-Erb B2) Reactivity Pattern with Histologic Grade, Tumor Size and Lymph Node Status in Breast Cancer. Asian Pacific Journal of Cancer Prevention, 9, 553-556.
[9]
Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.I. and Trotti, A. (2010) AJCC Cancer Staging Manual. 7th Edition, Springer, 347-376.
[10]
Makanjuola, S.B.L., Ayodele, S.D., Javid, F.A., Obafunwa, J.O., Oludara, M.A. and Popoola, A.O. (2014) Breast Cancer Receptor Status Assessment and Clinicopathological Association in Nigerian Women: A Retrospective Analysis. Journal of Cancer Research & Therapy, 2, 122-127. https://doi.org/10.14312/2052-4994.2014-19
[11]
Chirivella, I., Bermejo, A., Insa, A., Perez-Fidalgo, A., Magro, A., Rosello, S., Garcia-Garre, E., Martin, P., Bosch, A. and Lluch, A. (2006) Impact of Chemotherapy Dose-Related Factors on Survival in Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy. Journal of Clinical Oncology, 24, 668. https://doi.org/10.1200/jco.2006.24.18_suppl.668
[12]
Bonadonna, G., Moliterni, A., Zambetti, M., Daidone, M.G., Pilotti, S., Gianni, L., et al. (2005) 30 Years’ Follow Up of Randomized Studies of Adjuvant CMF in Operable Breast Cancer: Cohort Study. British Medical Journal, 330, 1-6. https://doi.org/10.1136/bmj.38314.622095.8F
[13]
Foote, M. (1998) The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice? Oncologist, 3, 365-368. https://doi.org/10.1634/theoncologist.3-5-365
[14]
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M. and Brambilla, C, (1995) Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer: The Results of 20 Years of Follow-Up. New England Journal of Medicine, 332, 901-906. https://doi.org/10.1056/NEJM199504063321401
[15]
Link, B., Budd., G., Scott, S., Dickman, E., Paul, D. and Lawless, G (2001) Delivering Adjuvant Chemotherapy to Women with Early-Stage Breast Cancer: Current Patterns of Care. Cancer, 92, 1354-1367. https://doi.org/10.1002/1097-0142(20010915)92:6%3C1354::AID-CNCR1458%3E3.0.CO;2-P
[16]
Lenhart., C. (2005) Relative Dose Intensity: Improving Cancer Treatment and Outcomes. Oncology Nursing Forum, 32, 757-764. https://doi.org/10.1188/05.ONF.757-764
[17]
Crawford, J., Dale, D., Kuderer, N., Culakova, E., Poniewierski, M., Wolff, D. and Lyman, G.H. (2008) Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice. Journal of the National Comprehensive Cancer Network, 6, 109-118. https://doi.org/10.6004/jnccn.2008.0012
[18]
Lyman, G.H. (2009) Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes. Journal of the National Comprehensive Cancer Network, 7, 99-108. https://doi.org/10.6004/jnccn.2009.0009
[19]
Skipper, H.E. (1971) Kinetics of Mammary Tumor Cell Growth and Implications for Therapy. Cancer, 28, 1479-1499. https://doi.org/10.1002/1097-0142(197112)28:6%3C1479::AID-CNCR2820280622%3E3.0.CO;2-M
[20]
Hershman, D., Weinberg, M., Rosner, Z., et al. (2003) Ethnic Neutropenia and Treatment Delay in African American Women Undergoing Chemotherapy for Early-Stage Breast Cancer. Journal of the National Cancer Institute, 95, 1545-1548. https://doi.org/10.1093/jnci/djg073
[21]
Folorunso S.A., Abiodun O.O., Abdus-Salam A.A. and Wuraola F.O. (2023) Evaluation of Side Effects and Compliance to Chemotherapy in Breast Cancer Patients at a Nigerian Tertiary Hospital. Ecancer Medical Science, 21, Article 1537. https://doi.org/10.3332/ecancer.2023.1537
[22]
Ademuyiwa, F.O., Edge, S.B., Erwin, D.O., Orom, H. and Ambrosone, C.B. (2010) Underwood III W Breast Cancer Racial Disparities: Unanswered Questions. Cancer Research, 71, 640-644. https://doi.org/10.1158/0008-5472.CAN-10-3021
[23]
Griggs, J.J., Sorbero, M.E., Stark, A.T., et al. (2003) Racial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy. Breast Cancer Research and Treatment, 81, 21-31. https://doi.org/10.1023/A:1025481505537
[24]
Smith, T.J., Khatcheressian, J., Lyman, G.H., et al. (2006) Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology, 24, 3187-3205. https://doi.org/10.1200/JCO.2006.06.4451
[25]
Chambers, P., Jani, Y., Wei, L., et al. (2019) Patient Factors and Their Impact on Neutropenic Events: A Systematic Review and Meta-Analysis. Support Care Cancer, 27, 2413-2424. https://doi.org/10.1007/s00520-019-04773-6
[26]
Bretzel., R.L., Rph, Jr., Cameron, R., Gustas, M., Garcia., M.A., Hoffman., H.K., Malhotra, R., et al. (2009) Dose Intensity in Early-Stage Breast Cancer: A Community Practice Experience. Journal of Oncology Practice, 5, 287-290. https://doi.org/10.1200/JOP.091036
[27]
Olatunji, T., Sowunmi, A., Ketiku, K., et al. (2019) Sociodemographic Correlates and Management of Breast Cancer in Radiotherapy Department, Lagos University Teaching Hospital: A 10-Year Review. Journal of Clinical Sciences, 16, 111-119. https://doi.org/10.4103/jcls.jcls_82_18
[28]
Gradishar, W.J., Anderson, B.O., Abraham, J., et al. (2020) Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18, 452-478.
[29]
Dange, V.N., Shid, S.J., Magdum, C.S., et al. (2017) A Review on Breast Cancer: An Overview. Asian Journal of Pharmaceutical Research, 7, 49-51. https://doi.org/10.5958/2231-5691.2017.00008.9
[30]
Wood, W.C., Buman, D.R., Korzun, A.H., Cooper, M.R., Yonger, J., Hart, R.D., Moore, A., Ellerton, J.A., Norton, L., Fereee, C.R., et al. (1994) Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. The New England Journal of Medicine, 330, 1253-1259. https://doi.org/10.1056/NEJM199405053301801
[31]
Hershman, D., McBride, R., Jacobson, J.S., et al. (2005) Racial Disparities in Treatment and Survival among Women with Early-Stage Breast Cancer. Journal of Clinical Oncology, 23, 6639-6646. https://doi.org/10.1200/JCO.2005.12.633
[32]
Lohrisch, C., Paltiel, C., Gelmon, K., et al. (2006) Impact on Survival of Time from Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer. Journal of Clinical Oncology, 24, 4888-4894. https://doi.org/10.1200/JCO.2005.01.6089
